Health Care Equipment

Omnicell

Omnicell released FY2026 Q1 earnings on April 28 Pre-Market (EST), actual revenue USD 309.88 M (forecast USD 304.06 M), actual EPS USD 0.25 (forecast USD -0.004)

Omnicell Releases Strategic Plan and New Product Titan XT

Omnicell to Release FY2026 Q1 Earnings on April 28 Pre-Market EST, Forecast Revenue USD 304.06 M, EPS USD -0.004

Omnicell released FY2025 Annual Earnings on February 5 Pre-Market (EST), Actual Revenue USD 1.185 B (Forecast USD 1.184 B), Actual EPS USD 0.04 (Forecast USD 0.295)

Omnicell released FY2025 Q4 earnings on February 5, Pre-Market (EST), actual revenue USD 313.98 M (forecast USD 313.36 M), actual EPS USD -0.0521 (forecast USD 0.2066)

Omnicell Releases 2025 Financial Results and Launches New Automated Drug Management System Titan XT

Omnicell to Release FY2025 Q4 Earnings on February 5, 2026 Pre-Market EST, Forecast Revenue USD 313.36 M, EPS USD 0.2066

Omnicell released FY2025 Q3 earnings on October 30 Pre-Market (EST), actual revenue USD 310.63 M (forecast USD 295.59 M), actual EPS USD 0.1199 (forecast USD 0.07)

Omnicell released FY2025 9 Months Earnings on October 30 Pre-Market (EST), actual revenue USD 870.86 M, actual EPS USD 0.0892

Omnicell Announces Pharmacy Transformation and Revenue Growth Strategy

Omnicell to release FY2025 Q3 earnings on October 30 Pre-Market EST, forecast revenue USD 295.59 M, EPS USD 0.07

Omnicell released FY2025 Semi-Annual earnings on July 31 Pre-Market (EST), actual revenue USD 560.23 M, actual EPS USD -0.03

Omnicell released FY2025 Q2 earnings on July 31 Pre-Market EST, actual revenue USD 0 (forecast USD 275.24 M), actual EPS USD 0 (forecast USD -0.038)

Omnicell to release FY2025 Q2 earnings report on July 31, pre-market EST, with forecast revenue of USD 275.24 M and EPS of USD -0.038

Omnicell Reports Q2 2025 Earnings

Omnicell's stock undervalued by 27%

Omnicell Announces CFO Nchacha Etta's Resignation

Omnicell Inc. Holds Annual Shareholders Meeting

B of A Securities Maintains Omnicell's Rating and Raises Target Price

Piper Sandler Raises Omnicell's Target Price to $57

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

OMCL

Omnicell's Q1 earnings call highlighted strong revenue growth of 15% year-over-year, reaching $310 million, and significant profitability improvements with non-GAAP EBITDA rising to $45 million. The company raised its full-year profit guidance while maintaining revenue targets. New product launches, including the Titan XT system, are expected to drive future growth. However, management acknowledged potential tariff-related costs and volatility in quarterly results due to product mix and timing.

Tip Ranks

Omnicell Earnings Call Highlights Profits and Momentum

Omnicell (OMCL) reported Q1 revenue of $309.9 million and EPS of $0.25, with trailing twelve-month revenue of $1.2 billion and a net margin of 1.7%. Despite bullish expectations for margin improvement driven by SaaS and automation, profitability remains volatile, with quarterly net income fluctuating significantly. The company's high P/E ratio of 95.9x raises concerns about valuation risks, especially given its mixed profitability history and slim margins. Analysts emphasize the need for consistent earnings growth to justify the current share price of $43.10, which exceeds its DCF fair value of $49.48.

Simplywall

Omnicell (OMCL) Q1 EPS Recovery Tests Bullish Margin Improvement Narrative

Omnicell (NASDAQ: OMCL) experienced a nearly 21% stock gain after reporting strong first-quarter earnings, with revenue rising almost 15% year-over-year to nearly $310 million, surpassing analyst expectations. Product revenue grew by 20% to nearly $175 million, while service revenue increased by 8% to $135 million. The company also more than doubled its net income to $25 million, exceeding forecasts. Management raised guidance for the current quarter and 2026, expecting revenue between $1.22 billion and $1.26 billion and adjusted net income per share of $1.80 to $2.00.

nasdaq

NVIDIA

Intel

Netflix

S&P 500

Nasdaq

NVIDIA Corporation

Why Omnicell Stock Trounced the Market on Tuesday

Omnicell's Q1 earnings call revealed a 15% revenue increase to $310 million, driven by strong demand in healthcare automation. Non-GAAP EBITDA surged 88% to $45 million, with non-GAAP EPS doubling to $0.55. The company raised its full-year profit guidance, maintaining product bookings expectations of $510-$560 million. Despite a 38% drop in cash to $239 million due to debt repayment and share buybacks, management emphasized disciplined capital allocation. New product launches, including Titan XT, are expected to drive future growth, although revenue contributions may be gradual due to lengthy approval cycles.

Omnicell Earnings Call Shows Profits Surging, Outlook Raised

KFRC

KNSA

SANM

CECO

COUR

CVLT

BBAI

Kforce.com(KFRC) rose 43.3%, with a trading turnover 79.1 Million USD, and a year-to-date rose 50.5%. Kiniksa Pharmaceuticals(KNSA) rose 23.48%, with a trading turnover 157.2 Million USD, and a year-to-date rose 30.5%. Omnicell(OMCL) rose 20.94%, with a trading turnover 98.9 Million USD, and a year-to-date rose 0.5%.

Top Gainers&Losers

Kforce.com

Kiniksa Pharmaceuticals

Sanmina

CECO Environmental

Centene

Thermon

Coursera

Commvault Systm

BigBear.ai

Top 10 US Stock Gainers (4.28)

Omnicell, Inc. reported strong Q1 2026 results with total revenue of $310 million, a 15% increase from Q1 2025. Product revenue rose to $174.8 million, while service revenue increased to $135.1 million. The company achieved a GAAP net income of $11 million, reversing a loss from the previous year. Non-GAAP net income was $25 million, with EBITDA at $45 million. Omnicell raised its 2026 outlook, expecting total revenue between $1.215 billion and $1.255 billion, and non-GAAP EPS of $1.80-$2.00. The stock is currently trading at $44.97, up 19.17%.

Omnicell Posts Strong Q1 Results, Lifts 2026 Profitability Outlook; Stock Up

Omnicell, Inc. reported strong first quarter 2026 financial results, with total revenues of $310 million, a 15% increase from the previous year. The company achieved a GAAP net income of $11 million and a non-GAAP net income of $25 million. Omnicell raised its full year 2026 non-GAAP EBITDA and EPS guidance, reflecting solid demand for its connected devices and core solutions. The company showcased its Titan XT and OmniSphere technologies at industry events and launched a new customer community for collaboration. Cash and cash equivalents stood at $239 million as of March 31, 2026.

StockTitan

Omnicell Announces First Quarter 2026 Financial Results | OMCL Stock News

Omnicell shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates. Also, the company raised its FY26 adjusted EPS guidance.

benzinga_article

HCWB

AXGN

In Tuesday's pre-market session, several health care stocks experienced significant movements. Notable gainers included Pomdoctor (POM) with a 30.4% rise to $0.39, Omnicell (OMCL) up 23.3% to $46.4, and Axogen (AXGN) increasing by 12.97% to $44.5. Conversely, Soligenix (SNGX) saw a sharp decline of 51.7% to $0.68, while Erasca (ERAS) fell 43.29% to $10.86. Other notable losers included iTonic Holdings (ITOC) down 13.34% and HCW Biologics (HCWB) down 12.62%.

Omnicell(OMCL.US)